Patents by Inventor David Margolis

David Margolis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200299309
    Abstract: The invention relates a compound of the formula: a pharmaceutically acceptable salt thereof, compositions thereof, and methods of therapeutic treatment using the same.
    Type: Application
    Filed: June 10, 2020
    Publication date: September 24, 2020
    Applicants: GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare Company
    Inventors: Richard M DUNHAM, David MARGOLIS, Vincent Wing-Fai TAI, Jun TANG
  • Publication number: 20200147079
    Abstract: A method of treating HIV comprising intramuscular administration once every 4 weeks or less frequently of a combination of cabotegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof, including the option of discontinuing administration of a first oral anti-retroviral regimen and intramuscularly administering, once four weeks or less often said combination of cabotegravir and rilpivirine.
    Type: Application
    Filed: July 18, 2018
    Publication date: May 14, 2020
    Inventors: Herta CRAUWELS, David MARGOLIS, William R. SPREEN, Andrew SPALTENSTEIN, Peter WILLIAMS
  • Patent number: 10592674
    Abstract: Digital obsolescence avoidance systems and methods may determine an obsolescence vulnerability for a digital object. A digital obsolescence avoidance system may include a validation system and an obsolescence vulnerabilities system. The validation system may be configured to receive metadata for the digital object and to determine a digital object kind for the received metadata. The obsolescence vulnerabilities system may be configured to determine one or more dependencies for the determined object kind, to determine an obsolescence vulnerability based on the determined one or more dependencies, and to provide output related to the determined obsolescence vulnerability.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: March 17, 2020
    Inventors: Linda Tadic, David Margolis, Diana Eppstein
  • Publication number: 20180018464
    Abstract: Digital obsolescence avoidance systems and methods may determine an obsolescence vulnerability for a digital object. A digital obsolescence avoidance system may include a validation system and an obsolescence vulnerabilities system. The validation system may be configured to receive metadata for the digital object and to determine a digital object kind for the received metadata. The obsolescence vulnerabilities system may be configured to determine one or more dependencies for the determined object kind, to determine an obsolescence vulnerability based on the determined one or more dependencies, and to provide output related to the determined obsolescence vulnerability.
    Type: Application
    Filed: July 14, 2017
    Publication date: January 18, 2018
    Inventors: Linda Tadic, David Margolis, Diana Eppstein
  • Publication number: 20130203653
    Abstract: This invention relates to a treatment of acne. Specifically, the invention is directed to the use of bacteriocin-like inhibitory substances (BLIS), isolated from S. salivarius as bacteriocide or bacteriostat for acne-causing bacteria, namely P. acnes.
    Type: Application
    Filed: April 8, 2013
    Publication date: August 8, 2013
    Inventors: Whitney BOWE, David Margolis
  • Patent number: 8415289
    Abstract: This invention relates to a treatment of acne. Specifically, the invention is directed to the use of bacteriocin-like inhibitory substances (BLIS), isolated from S. salivarius as bactericide or bacteriostat for acne-causing bacteria, namely P. acnes.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: April 9, 2013
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David Margolis, Whitney Bowe
  • Publication number: 20100056423
    Abstract: This invention relates to a treatment of acne. Specifically, the invention is directed to the use of bacteriocin-like inhibitory substances (BLIS), isolated from S. salivarius as bactericide or bacteriostat for acne-causing bacteria, namely P. acnes.
    Type: Application
    Filed: December 13, 2006
    Publication date: March 4, 2010
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David Margolis, Whitney Bowe
  • Publication number: 20050129661
    Abstract: An integrative DNA vector and one or more viral proteins having affinity for DNA are packaged in cochleate precipitates. The integrative DNA vector contains one or more therapeutic nucleotide sequences that are preferably positioned between DNA substrates for the proteins. Upon contact with a lipid bilayer of a target cell, the cochleate vector structure delivers one or more of the therapeutic nucleotide sequences and one or more proteins to the interior of the target cell. Upon entry into the cell, the proteins facilitate the integration of the therapeutic nucleotide sequence into the genome of the host cell.
    Type: Application
    Filed: January 24, 2005
    Publication date: June 16, 2005
    Applicants: University of Medicine and Dentistry of New Jersey, University of Maryland
    Inventors: David Margolis, Susan Gould-Fogerite, Raphael Mannino
  • Patent number: 6514979
    Abstract: Synergistic combinations of guanosine nucleoside analog reverse transcriptase inhibitors such as abacavir with inosine monophosphate dehydrogenase inhibitors such as mycophenolates, pharmaceutical compositions comprising such combinations, and therapeutic methods comprising administering the synergistic combinations to subjects in need thereof, for treating a viral infection, such as an HIV-1 infection.
    Type: Grant
    Filed: March 3, 1999
    Date of Patent: February 4, 2003
    Assignee: University of Maryland Biotechnology Institute
    Inventors: David Margolis, Alonso Heredia, David Oldach, Robert Redfield
  • Patent number: 6456600
    Abstract: A method of calculating a complex node representation for logical nodes in a hierarchical peer group in a PNNI based ATM network. The summary information for default spokes, exceptions and bypasses is determined in a way that closely represents the underlying metrics associated with the peer group. A list of all border nodes in the peer group is generated and maintained and a matrix of tables is generated, one table for each metric per each class of service. The table is populated by the best value associated with the corresponding metric for a particular pair of border nodes within a particular class of service. Once the table is populated, each element is placed in a group or bin. The bins are generated by dividing the full range of the metric into a plurality of smaller subgroups or bins. The bin having a count greater than a threshold count is selected and 80% of the worst value for that group is used as the default spoke.
    Type: Grant
    Filed: April 28, 1999
    Date of Patent: September 24, 2002
    Assignee: 3Com Corporation
    Inventors: Haim Rochberger, Meir Morgenstern, David Margolis
  • Publication number: 20020034822
    Abstract: An integrative DNA vector and one or more viral proteins having affinity for DNA are packaged in cochleate precipitates. The integrative DNA vector contains one or more therapeutic nucleotide sequences that are preferably positioned between DNA substrates for the proteins. Upon contact with a lipid bilayer of a target cell, the cochleate vector structure delivers one or more of the therapeutic nucleotide sequences and one or more proteins to the interior of the target cell. Upon entry into the cell, the proteins facilitate the integration of the therapeutic nucleotide sequence into the genome of the host cell.
    Type: Application
    Filed: September 21, 2001
    Publication date: March 21, 2002
    Applicant: UNIVERSITY OF MARYLAND
    Inventors: David Margolis, Susan Gould-Fogerite, Raphael James Mannino
  • Patent number: 6340591
    Abstract: An integrative DNA vector and one or more viral proteins having affinity for DNA are packaged in cochleate precipitates. The integrative DNA vector contains one or more therapeutic nucleotide sequences that are preferably positioned between DNA substrates for the proteins. Upon contact with a lipid bilayer of a target cell, the cochleate vector structure delivers one or more of the therapeutic nucleotide sequences and one or more proteins to the interior of the target cell. Upon entry into the cell, the proteins facilitate the integration of the therapeutic nucleotide sequence into the genome of the host cell.
    Type: Grant
    Filed: December 14, 1998
    Date of Patent: January 22, 2002
    Assignees: University of Maryland, University of Medicine and Dentistry of New Jersey
    Inventors: David Margolis, Susan Gould-Fogerite, Raphael James Mannino